Treat-to-target or treat-to-dissolve strategy to improve gout treatment

Competing interests

P.R. received fees from Horizon. N.D. received fees from AstraZeneca, Novartis, Horizon, Selecta, Arthrosi, JW Pharmaceutical Corporation, PK Med, LG Chem, JPI, PTC Therapeutics, Protalix, Unlocked Labs, Hikma, Dexcel Pharma, Shanton Pharma and Avalo outside the submitted work.

留言 (0)

沒有登入
gif